Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin

Thrombosis and Haemostasis

Volumn 95, Issue 4, 2006, Pages 637-642

  Nakamura, Ryuta ^a   Umemura, Kazuo ^a   Hashimmoto, Hisakuni ^a   Urano, Tetsumei ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Low molecular weight heparin; Plasminogen activator inhibitor type I; Thrombin; Unfractionated heparin; Vitronectin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; VITRONECTIN;

ANTICOAGULATION; ARTICLE; BLEEDING TENDENCY; BLOOD CLOTTING; COMPLEX FORMATION; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFECT; FIBRINOLYSIS; HUMAN; HUMAN TISSUE; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN INTERACTION;

BLOOD COAGULATION; CALCIUM; FACTOR XA; FIBRINOLYSIS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT PROTEINS; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; VITRONECTIN;

EID: 33645741665     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-07-0507     Document Type: Article

References (37)

1. Loskutoff DJ, et al. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 1989; 9: 87-115.
2. Urano T, et al. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1. Thromb Haemost 1990; 63: 82-6.
3. Berrettini M, et al. Interaction of type 1 plasminogen activator inhibitor with the enzymes of the contact activation system. J Biol Chem 1989; 264: 11738-43.
4. Ehrlich HJ, et al. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem 1990; 265: 13029-35.
5. Keijer J, et al. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site. Blood 1991; 78: 1254-61.
6. Urano T, et al. The inhibition of human factor Xa by plasminogen activator inhibitor type 1 in the presence of calcium ion, and its enhancement by heparin and vitronectin. Biochim Biophys Acta 1996; 1298: 199-208.
7. Urano T, et al. Human thrombin and calcium bound factor Xa significantly shorten tPA-induced fibrin clot lysis time via neutralization of plasminogen activator inhibitor type 1 activity. Thromb Haemost 1998; 80: 161-6.
8. Urano T, et al. Coagulation-associated enhancement of fibrinolytic activity via a neutralization of PAI-1 activity. Semin Thromb Hemost 2000; 26: 39-42.
9. Gaffney PJ, et al. The haemostatic balance -- Astrup revisited. Haemostasis 1999; 29: 58-71.
10. Hull RD, et al. Subcutaneous low-molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-82.
11. Fiessinger JN, et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996; 76: 195-9.
12. Holmer E, et al. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin. Biochem J 1981; 193: 395-400.
13. Urano T, et al. A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate. Eur J Biochem 1992; 209: 985-92.
14. Jameson GW, et al. Determination of the operational molarity of solutions of bovine alpha-chymotrypsin, trypsin, thrombin and factor Xa by spectrofluorimetric titration. Biochem J 1973; 131: 107-17.
15. Urano T, et al. Activated protein C attenuates coagulation-associated over-expression of fibrinolytic activity by suppressing the thrombin-dependent inactivation of PAI-1. J Thromb Haemost 2003; 1: 2615-20.
16. Urano T, et al. Soluble thrombomodulin quenches thrombin-mediated neutralization of PAI-1 activity and inhibits fibrinolysis through a TAFI independent mechanism. Fibrinolysis Proteolysis 1999; 13: 264-71.
17. Fears R. Kinetic studies on the effect of heparin and fibrin on plasminogen activators. Biochem J 1988; 249: 77-81.
18. Sakata Y, et al. Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood 1986; 68: 1218-23.
19. Wu K, et al. The cleavage and inactivation of plasminogen activator inhibitor type 1 by neutrophil elastase: the evaluation of its physiologic relevance in fibrinolysis. Blood 1995; 86: 1056-61.
20. Urano T, et al. The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis cleaves and inactivates plasminogen activator inhibitor type 1. J Biol Chem 2001; 276: 24690-6.
21. Sui GC, Wiman B. Functional effects of single amino acid substitutions in the region of Phe 113 to Asp 138 in the plasminogen activator inhibitor 1 molecule. Biochem J 1998; 331: 409-15.
22. Ehrlich HJ, et al. Elucidation of structural requirements on plasminogen activator inhibitor 1 for binding to heparin. J Biol Chem 1992; 267: 11606-11.
23. Gebbink RK, et al. Specific glycosaminoglycans support the inhibition of thrombin by plasminogen activator inhibitor 1. Biochemistry 1993; 32: 1675-80.
24. Ehrlich HJ, et al. Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin. Biochemistry 1991; 30: 1021-8.
25. Rezaie AR. Role of exosites 1 and 2 in thrombin reaction with plasminogen activator inhibitor- 1 in the absence and presence of cofactors. Biochemistry 1999; 38: 14592-9.
26. Huntington JA. Mechanisms of glycosaminoglycan activation of the serpins in hemostasis. J Thromb Haemost 2003; 1: 1535-49.
27. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-92.
28. Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-74.
29. Siragusa S, et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a metaanalysis. Am J Med 1996; 100: 269-77.
30. Lensing AW, et al. Treatment of deep venous thrombosis with low-molecular-weight heparins. A metaanalysis. Arch Intern Med 1995; 155: 601-7.
31. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-98.
32. Warkentin TE, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
33. Marini C, et al. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial. Respiration 1988; 54: 162-73.
34. Stassen JM, et al. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator. Thromb Haemost 1987; 58: 947-50.
35. Vairel EG, et al. Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. Thromb Res 1983; 30: 219-24.
36. Lisman T, De Groot PG. Rebuttal to: Effect of heparin on TAFI-dependent inhibition of fibrinolysis. J Thromb Haemost 2003; 1: 200-1.
37. Chesebro JH, et al. Conjunctive antithrombotic therapy for thrombolysis in myocardial infarction. Am J Cardiol 1993; 72: 66G-74G.